CO6241117A2 - Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas - Google Patents
Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativasInfo
- Publication number
- CO6241117A2 CO6241117A2 CO09135758A CO09135758A CO6241117A2 CO 6241117 A2 CO6241117 A2 CO 6241117A2 CO 09135758 A CO09135758 A CO 09135758A CO 09135758 A CO09135758 A CO 09135758A CO 6241117 A2 CO6241117 A2 CO 6241117A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- hydrogen
- group
- cyano
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
1.- Un compuesto de la Fórmula Ien donde: uno entre A1, A2 o A3 es N, y los otros son independientemente seleccionados a partir de CH o N; R1 es un grupo (1- 4C) alquilo el cual es opcionalmente sustituido por uno o más grupos sustituyentes seleccionados a partir de -OR5 (en donde R5 es seleccionado a partir de hidrógeno o (1- 2C) alquilo) ciano, halo, o - NR R (donde R6 y R7 son independientemente seleccionados a partir de hidrógeno, (1- 2C) alquilo o (1- 2C) alcanoilo); n es 0, 1, 2 o 3;cada grupo R2 presente es independientemente seleccionado a partir de (1-2C) alquilo, (1-2C) alcoxilo, fluoro, cloro, ciano, hidroxi(1- 2C) alquilo, o un grupo de la sub- Fórmula: - Q - R8 donde Q es seleccionado a partir de - CO- , - NRa- , - NRa- CO-, -NRa-COO-, NRaCONRb, -CONRa-, -S(O)z- (donde z es 0, 1 o 2); -SO2NRa-, y -NRaSO2-, Ra y Rb son cada uno independientemente seleccionados a partir de hidrógeno o metilo, y R8 es hidrógeno o (1-2C) alquilo; R3 es seleccionado a partir de: (v) hidrógeno, halo, nitro, ciano, o hidroxilo; (vi) un grupo (1-6C) alquilo, (2-6C) alquenilo, o (2-6C) alquinilo opcionalmente sustituido en donde los sustituyentes opcionales son seleccionados a partir de: ciano; halo; un grupo de sub-Fórmula: en donde W es seleccionado a partir de -O-, -S(O)p- (donde p es 0, 1 o 2), -CO-, -NRbCO-, -CONRb-, - NRbCONRb-, -SO2NRb, -NRbSO2-, o -NRbCOO-; Rb es seleccionado a partir de hidrógeno o (1- 2C) alquilo;y R9 es seleccionado a partir de hidrógeno o (1-4C) alquilo; o -NR10R11, donde R10 y R11, son independientemente seleccionados a partir de hidrógeno, o (1-2C) alquilo, o R10 y R11 son enlazados para formar un anillo heterocíclico de 4, 5, 6 o 7 miembros el cual opcionalmente comprende, además del átomo de nitrógeno al cual R10 y R11 están unidos, uno o dos heteroátomos adicionales seleccionados a partir de O, N o S, y en donde cualquiera de los átomos S que están presentes se pueden opcionalmente oxidar para formar un grupo SO y SO2, y en donde cualquier átomo de carbono presente en el anillo es opcionalmente ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07301001 | 2007-04-27 | ||
EP07301002 | 2007-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6241117A2 true CO6241117A2 (es) | 2011-01-20 |
Family
ID=39739252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09135758A CO6241117A2 (es) | 2007-04-27 | 2009-11-27 | Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090036440A1 (es) |
EP (1) | EP2150545A1 (es) |
JP (1) | JP2010525047A (es) |
KR (1) | KR20100017441A (es) |
AU (1) | AU2008244026A1 (es) |
CA (1) | CA2687943A1 (es) |
CO (1) | CO6241117A2 (es) |
EC (1) | ECSP099767A (es) |
NZ (1) | NZ581397A (es) |
RU (1) | RU2009143753A (es) |
WO (1) | WO2008132505A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009010789A2 (en) | 2007-07-16 | 2009-01-22 | Astrazeneca Ab | Pyrimidine derivatives 934 |
US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
HRP20240097T1 (hr) | 2011-04-22 | 2024-03-29 | Signal Pharmaceuticals, Llc | Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
WO2016100310A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
CN110357832B (zh) * | 2019-07-08 | 2022-03-15 | 武汉大学 | 一种芳香胺类化合物及EphB4激酶抑制剂及其衍生物的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ531853A (en) * | 2001-11-01 | 2006-02-24 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
CA2512646A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
CN105348203B (zh) * | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
AU2008221278A1 (en) * | 2007-03-01 | 2008-09-04 | Supergen, Inc. | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors |
-
2008
- 2008-04-25 CA CA002687943A patent/CA2687943A1/en not_active Abandoned
- 2008-04-25 EP EP08737220A patent/EP2150545A1/en not_active Withdrawn
- 2008-04-25 US US12/109,618 patent/US20090036440A1/en not_active Abandoned
- 2008-04-25 RU RU2009143753/04A patent/RU2009143753A/ru not_active Application Discontinuation
- 2008-04-25 WO PCT/GB2008/050295 patent/WO2008132505A1/en active Application Filing
- 2008-04-25 JP JP2010504863A patent/JP2010525047A/ja active Pending
- 2008-04-25 KR KR1020097024790A patent/KR20100017441A/ko not_active Application Discontinuation
- 2008-04-25 AU AU2008244026A patent/AU2008244026A1/en not_active Abandoned
- 2008-04-25 NZ NZ581397A patent/NZ581397A/en not_active IP Right Cessation
-
2009
- 2009-11-27 CO CO09135758A patent/CO6241117A2/es not_active Application Discontinuation
- 2009-11-27 EC EC2009009767A patent/ECSP099767A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20090036440A1 (en) | 2009-02-05 |
WO2008132505A1 (en) | 2008-11-06 |
ECSP099767A (es) | 2009-12-28 |
JP2010525047A (ja) | 2010-07-22 |
NZ581397A (en) | 2012-02-24 |
RU2009143753A (ru) | 2011-06-10 |
EP2150545A1 (en) | 2010-02-10 |
AU2008244026A1 (en) | 2008-11-06 |
CA2687943A1 (en) | 2008-11-06 |
KR20100017441A (ko) | 2010-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6241117A2 (es) | Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas | |
ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
WO2008152072A3 (de) | Piperazinverbindungen mit herbizider wirkung | |
AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
AR078793A1 (es) | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros | |
PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
PE20011259A1 (es) | Derivado de piridina y pirimidina | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
AR049551A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa | |
CO6220878A2 (es) | Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
UY30323A1 (es) | Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |